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Introduction. Endothelial dysfunction and inﬂammation play a key role in the development of atherosclerosis. The present study
evaluated endothelial function, inﬂammatory parameters, and carotid intima-media thickness (IMT) in dyslipidemic patients
with or without coronary artery disease (CAD). Methods. Metabolic proﬁle and inﬂammatory parameters were determined
in dyslipidemic patients with (+CAD, n = 33) and without (−CAD, n = 69) symptomatic CAD. Endothelial function was
evaluated by ﬂow mediated dilatation (FMD) and plasma concentration of nitrites and nitrates. Carotid IMT was measured by
ultrasound. Results. No signiﬁcant diﬀerences were observed in anthropometric hemodynamic or metabolic parameters between
the groups. After adjusting by age and medication usage, some inﬂammatory markers were signiﬁcantly higher in +CAD; however
no signiﬁcant diﬀerences in FMD or plasma levels of nitrites were observed. Conclusions. In subjects with dyslipidemia, the
presence of CAD is associated with an elevation of certain inﬂammatory markers and carotid IMT but not with further endothelial
dysfunction.
Copyright © 2009 Christian F. Rueda-Clausen et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Dyslipidemia together with hypertension and diabetes is
major modiﬁable risk factor for atherosclerotic disease and
the subsequent development of cardiovascular events [1–
4]. Endothelial dysfunction, which is a condition that has
been strongly associated with dyslipidemia, plays a key
role in the development and progression of atherosclerosis
[5], and it is known to be an independent predictor for
cardiovascularevents[6,7].Thereducedavailabilityofnitric
oxide (NO) resulting from both a decreased synthesis and/or
an enhanced degradation by reactive oxygen species seems to
be the major cause of endothelial dysfunction documented
in subjects with cardiovascular risk factors including dys-
lipidemia [8]. It is also well accepted that atherosclerosis
can be considered a chronic vascular inﬂammatory disease
[9]. Inﬂammatory cytokines are responsible for activation of
endothelial cells, a condition characterized by the expression
of endothelial cell-surface adhesion molecules such as vas-
cular cell adhesion molecule-1 (sVCAM-1) and p-Selectin,
that favor the attachment of circulating monocytes to the
endothelium [10] and their migration and diﬀerentiation
in the vascular intima-media layer [11]. The consequence
of this persistent migration and cellular diﬀerentiation in
the subendothelial vascular layers causes an increase in
the arterial intima-media thickness, which is considered a
highlysensitivemarkerofatherosclerosisprogression[6,12].
Similarly,C-reactiveprotein(CRP),whichisawell-described
inﬂammatory marker, has been shown to be an independent
predictors of future cardiovascular events in both high-risk
and healthy subjects [13–15]. Moreover, increased circulat-
ing cytokines including tumor necrosis factor alpha (TNFα),
interleukin-1 beta(IL-1β),andinterleukin-6 (IL-6)havealso
been associated with cardiovascular events [16]. However,
it remains unclear whether the evaluation of endothelial
function and inﬂammatory markers reﬂects the same stage2 Mediators of Inﬂammation
in the progression and severity of atherosclerotic disease. A
question that is particularly relevant for populations from
developing countries who are know to be more susceptible
to develop proinﬂammatory states and insulin resistance
[17]. In order to clarify these aspects, the present paper
aimed to evaluate endothelial function, plasma levels of
inﬂammatory markers, and carotid intima-media thickness
(IMT) as well as the changes in these parameters associated
with the presence of clinically documented coronary artery
disease (CAD) in dyslipidemic patients.
2. Methods
This study included 102 dyslipidemic (LDL Cholesterol
>3.33mmol/L) male patients (25 to 77 years of age) dis-
tributed in two groups: subjects without history of cardio-
vascular events or clinical symptoms of coronary disease
(−CAD, n = 69) and patients with clinically diagnosed CAD
(+CAD, n = 33). The clinical criteria for diagnosis of CAD
included history of acute myocardial infarction (n = 12),
coronary artery bypass grafting (n = 13), coronary hearth
disease diagnosed by arteriography (n = 6), and chronic
stableangina(n = 2)diagnosedatleast6monthspreviousto
the evaluation. Exclusion criteria included: body mass index
>35, history of secondary or familiar hypercholesterolemia,
diabetesmellitus,abnormalliverfunction,renalimpairment,
clinical heart failure (NYHA classes III-IV), clinical vascular
events (transitory ischemic accident, peripheral arteries
occlusion, or mesenteric artery occlusion) during the last
six months, chronic inﬂammatory diseases, and acute illness
or major trauma in the last eight weeks. Due to the well-
describedeﬀectsoflipidloweringmedicationsonendothelial
function and inﬂammatory markers [18–20], and in order
to avoid the potential confusion in the data analysis and
interpretation, only those subjects who were not receiving
this kind of medication at least 3 months previous to the
evaluation were included in the study. Given the known
variability in the determinations of endothelial function and
inﬂammatory markers among diﬀerent laboratories, and in
order to have a reference point to identify the “normal
values” of these parameters, a group of 25 healthy young
volunteers was also studied.
A complete medical examination that included cardio-
vascular risk factor evaluation, vital signs, and anthro-
pometrical measurements (following the Anthropometry
Procedures Manual NHANES-2002 [21]) was performed
on every subject. Fasting venous blood samples were taken
for determination of glucose, creatinine, total cholesterol
(TC), HDL cholesterol (HDLc), LDL cholesterol (LDLc),
and triglycerides (TG), using standard techniques. Plasma
concentrations of IL-6, IL-1β,T N F α, and soluble fractions
of sVCAM-1 and p-Selectin, were measured with quan-
titative sandwich enzyme immunoassay techniques (R&D
Systems, Minneapolis, Minn, USA) as previously described
[18]. Ultrasensitive CRP plasma levels were measured with
a highly sensitive latex-based turbidimetric immunoassay
on a Hitachi analyzer (Sigma Chemical Co, St. Louis,
Mo, USA). The concentration of nitrites and nitrates,
the stable metabolites of NO [22], was determined in
plasma samples obtained after 24 hours of nitrate free diet,
using a commercial kit (R&D Systems) that involved the
conversion of nitrates to nitrites by the enzyme nitrate
reductase.
Flow mediated dilation (FMD) assessment was per-
formed according to the recommendations of the “Inter-
national Brachial Artery Reactivity Task Force” [23]. This
technique was validated by our group in a Colombian
population and published elsewhere [24, 25]. All measures
wereperformedinatemperature-controlledroom(24◦C),in
the morning, with a fasting period of at least 10 hours in all
the subjects. Brachial artery diameter and blood ﬂow veloc-
ity were imaged using a 7.5-MHz linear-array transducer
ultrasound system (Aloka, Vario view SDD 2200, Tokyo,
Japan), located between four and ten centimeters above the
antecubital fossa. A baseline measurement of brachial artery
diameter was obtained, as well as a baseline measurement of
thevelocityofthearterialﬂow,bymeansofapulsedDoppler
signal of the vessel. After baseline measurements, a small-
width blood pressure cuﬀ was inﬂated on the most proximal
portion of the forearm to occlusive pressure (300mmHg)
for ﬁve minutes in order to induce hyperemia. The cuﬀ
was then deﬂated, and pulsed Doppler signals were recorded
for 15 seconds. Images of the brachial artery were obtained
after 60 seconds of cuﬀ deﬂation. Vessel diameters were
measured with ultrasonic calipers from the leading edge of
the anterior wall to the leading edge of the posterior wall
of the brachial artery at end diastole, incident with the
R wave on the simultaneously recorded electrocardiogram.
Changesindiameterwerecalculatedaspercentagesofchange
relative to the baseline diameter. All images were recorded
on Super VHS tape for later analysis. The studies were
subsequently analyzed by two blinded observers; the mean
values obtained from the two observers were used for
analysis. The correlation in FMD between observers was
97.1% P<. 00001, and the coeﬃcient of variation was
8.59%. The carotid arteries were imaged with a Hewlett-
Packard,Sonos1500,Andover,Mass,USAultrasoundsystem
with a lineal 7.5MHz linear-array transducer. A depth of
4cm was used. The examination included a thorough scan
of the extracranial carotid arteries. The carotid IMT of the
distal 1cm of the far wall of the common carotid artery
was performed using a semiautomated border-detection
program by one single observer who was blinded to the
clinical condition of the subject. The mean carotid IMT
was calculated by averaging 3 measurements obtained at 3
scan planes (anterior, lateral, and posterior) from both the
right and left common carotid arteries using the standard
technique [26].
Before being included, and after full explanation of the
purpose of the study, written consent was obtained from
each subject. This study was carried out in adherence to
the declaration of Helsinki and approved by the Ethics
Committee of the Fundaci´ on Cardiovascular de Colombia.
2.1. Statistical Analyses. Student’s t-test and Mann-Whitney
tests were used to detect diﬀerences between groups accord-
ing to the data distribution. To evaluate diﬀerences in
vascular and inﬂammatory factors between groups andMediators of Inﬂammation 3
Table 1: Anthropometrical, metabolic and biochemical charac-
teristics of subjects with (+CAD) and without (−CAD) coronary
artery disease.
−CAD (n = 69) +CAD (n = 33)
Median (IQR) Median (IQR)
Age (years) 50.7 (44.3–57.7) 58.4 (52.5–66.6)∗
BMI (Kg/m2) 25.6 (24.3–27.3) 25.1 (22.5–26.9)
Waist
Circumference
(cm)
91.2 (84–96) 89.5 (82.2–97.6)
Hip Circumference
(cm)
92.5 (86.7–98) 91.5 (86–98)
W/H 0.98 (0.96–1.01) 0.98 (0.95–1.02)
SBP (mmHg) 120 (110–131) 125.5 (112.5–140)
DBP (mmHg) 79 (70–87.5) 79.5 (70–86.5)
Alanine
aminotranferease
(UI/L)
28 (22–36) 24 (18–32)
Aspartate
aminotransferase
(UI/L)
22 (19–25) 22 (17–25)
Glucose (mmol/L) 5.2 (4.9–5.5) 5.2 (5.01–5.61)
Creatinine
(μmol/L)
96.3 (87.5–104.3) 97.6 (85.7–105.2)
TC (mmol/L) 6.5 (5.98–7.18) 6.04 (5.53–6.89)
HDLc (mmol/L) 0.93 (0.8–1.07) 0.90 (0.77–1.07)
LDLc (mmol/L) 4.45 (3.77–5.01) 4.49 (3.93–5.06)
TG (mmol/L) 2.14 (1.68–2.86) 1.62 (1.21–2.40)∗
BMI: Body mass index; W/H: Waist to hip ratio; SBP: Systolic blood
pressure; DBP: Diastolic blood pressure; Glucose: Fasting plasma glucose;
Creatinine: Creatinine plasma levels; TC: Total cholesterol plasma con-
centration; HDLc: High density lipoprotein plasma concentration; LDLc:
Low density lipoprotein plasma concentration; TG: Triglyceride plasma
concentration. IQR: Interquartile range. ∗P<. 05 versus −CAD.
minimize possible interaction and confusion resulting from
diﬀerences in basal parameters, we used an analysis of
covariance (ANCOVA) that included the presence of CAD
as a dependent variable and age, TG leves, and medication
usageascovariates.Thecorrelationbetweentheplasmalevels
of vascular and inﬂammatory parameters was evaluated by
Spearmancorrelation analysisand a simple linear regression.
AP-value<.05wasconsideredstatisticallysigniﬁcant.Statis-
tical analyses were performed with Stata Statistical Software:
Release 10.0SE. (College Station, Tex, Stata Corporation).
3. Results
Subjects’ baseline characteristics are shown in Table 1.
Excluding age and TG plasma concentration (patients +CAD
wereslightlyolder,andpatients–CADhadhigherTGplasma
levels), no signiﬁcant diﬀerences were observed in any
anthropometric,metabolic,hemodynamic,orrenalfunction
parameters between the groups. Calcium channel blockers,
beta-adrenergic blocking drugs, and salicylic acid were more
commonly used by +CAD subjects (Table 2).
Table 2:Permanentmedicationusageindyslipidemicsubjectswith
(+CAD) and without (−CAD) coronary artery disease.
−CAD (n = 69) +CAD (n = 34)
Medication Permanent usage % Permanent usage %
ACEIs 17.4 32.4
Aspirin 21.7 73.5∗
NSAI 26.1 17.6
CCA 7.2 26.5∗
Beta blockers 4.3 61.8∗
Digoxin 1.4 2.9
Furosemide 2.9 0.0
Hydrochlorothiazide 2.9 8.8
Clopidogrel 0.0 2.9
ACEIs: Angiotensin-converting enzyme inhibitors, NSAI: Nonsteroidal
anti-inﬂammatory agents, CCA: Calcium channel antagonists, ∗: P<. 005
versus –EC.
After adjusting for age, TG, and medication usage,
no signiﬁcant diﬀerences in FMD (ANCOVA P = .49)
or plasma levels of nitrites (ANCOVA P = .54) were
observedbetweenpatientswithandwithoutCAD(Figure 1).
However, carotid IMT was signiﬁcantly higher in subjects
+CAD (ANCOVA P = .01) (Figure 1). Plasma levels of CRP,
IL-6, and sVCAM-1 were higher (ANCOVA P<. 05) in
subjects+CADwhencomparedtosubjects–CAD(Figure 2).
There were no statistically signiﬁcant diﬀerences in plasma
concentrations of TNFα,I L - 1 β, and p-Selectin between
the groups (Figure 2). Analyses of covariance showed no
signiﬁcantinteractionbetweenageandanyoftheendothelial
or inﬂammatory parameters evaluated between the groups
(P for interaction >.05). Table 3 shows values obtained from
25 healthy young Colombian subjects that were used in
the study as reference values for normal conditions in our
laboratory. Both groups of dyslipidemic patients (+CAD as
well as −CAD) showed signiﬁcantly lower values of FMD
and levels of nitrites as well as higher carotid IMT and
inﬂammatory markers than those from the reference group.
Moreover, the carotid IMT was positively and signiﬁcantly
correlated to the plasma levels of CRP, IL-6, and sVCAM-1
in +CAD but not in −CAD subjects (Figure 3).
4. Discussion
The present study shows that dyslipidemic patients with a
clinically documented history of CAD have higher concen-
trations of CRP, IL-6, and sVCAM-1 when compared to
dyslipidemic patients without history of CAD. Interestingly,
this elevation in certain inﬂammatory markers was not asso-
ciated with any further impairment of endothelial function
but was associated with a higher carotid IMT. Moreover, a
positive correlation between the carotid IMT and plasma
levels of certain inﬂammatory markers was present only in
subjects +CAD. All together, these results suggest that there
is an association between inﬂammation and the presence of
a more severe stage of CAD.4 Mediators of Inﬂammation
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Figure 1: Box and whisker plots of carotid intima-media thickness,
ﬂow mediated dilation and plasma concentration of nitrites and
nitrates in dyslipidemic subjects with (+CAD; n = 33) or without
(−CAD; n = 69) symptomatic coronary artery disease (CAD).
∗P<. 05 versus −CAD. Dotted lines represent the median of the
values obtained from healthy subjects in the same laboratory.
In the previous years, a growing body of evidence
has demonstrated the presence of endothelial dysfunction
and increased concentrations of inﬂammatory markers in
subjects with cardiovascular risk factors such as dyslipi-
demia [27, 28]. Furthermore, numerous reports support the
importance of inﬂammatory markers as independent risk
factors for cardiovascular events [15]. The results of the
present study further support the concept that dyslipidemia
is associated with endothelial function impairment and
elevation of inﬂammatory markers [29, 30]. As expected,
and independently of the presence of CAD, dyslipidemic
Table 3: Reference values obtained from 25 healthy young Colom-
bian subjects.
Variable Median (IQR)
FMD (%) 10.74 (7.9–13.5)
Nitrites (mmol/L) 29.8 (22.8–32.9)
IMT (mm) 0.31 (0.23–0.42)
CRP (mg/dL) 0.15 (0.12–0.17)
IL-6 (pg/mL) 1.21 (0.72–1.92)
IL-1β (pg/mL) 0.34 (0.23–0.8)
TNFα (pg/mL) 1.06 (0.53–1.59)
sVCAM-1 (ng/mL) 425.5 (374–584)
P-Selectin (ng/mL) 66.8 (52–85)
FMD: Flow mediated dilation, IMT: Carotid intima-media thickness, CRP:
plasma concentrations of C-reactive protein, IL-6: Interleukin 6, IL-1β:
Interleukin 1beta, TNFα: Tumor necrosis factor alpha, sVCAM-1: Vascular
adhesion molecule 1; IQR: Interquartile range.
patients had lower FMD and plasma nitrites as well as higher
concentrations of CRP, IL-6, IL-1β,T N F α, and sVCAM-1
and carotid IMT than the reference healthy group.
This study also demonstrated that markers of endothelial
dysfunction and inﬂammation were impaired in a dif-
ferential manner depending on the existence of clinically
diagnosed CAD. Endothelial dysfunction, evaluated by FMD
and plasma levels of nitrates, was present to a comparable
extent in both groups of patients, with or without CAD.
Nevertheless, in those patients with a history of CAD, carotid
IMT and some of the inﬂammatory markers measured (CRP,
IL-6, and sVCAM-1) were higher than in patients without
CAD. This indicates several aspects to be considered. One,
that endothelial dysfunction and inﬂammatory markers do
not represent the same degree of atherosclerosis progression
(carotid IMT was higher in +CAD than in –CAD), nor
the same degree of severity of cardiovascular disease. Two,
that further elevation of inﬂammatory markers does not
necessarily involve further reduction of FMD but does
involve an augmentation of carotid IMT. Therefore, these
ﬁndings suggest that once endothelial function is impaired
by the presence of dyslipidemia, the presence of CAD
is not associated with further impairment of endothelial
function at least several months after the occurrence of
the cardiovascular event. These results are consistent with a
study recently published showing that, in older adults, the
strongest predictors of cardiovascular events were age, sex,
and blood pressure, and that FMD had a minimal eﬀect on
the evaluation of risk in this population [31, 32]. Moreover,
the progression of atherosclerosis seems to be more severe in
patients +CAD because they presented with a higher carotid
IMT, which was also correlated with higher levels of CRP, IL-
6, and sVCAM-1.
One of the interesting aspects of the study lies in the
fact that none of the dyslipidemic subjects included received
any lipid lowering medication, allowing us to evaluate
the association between endothelial function, inﬂammatory
markers, and clinical outcomes without the potential con-
fusion caused by the well-described anti-inﬂammatory and
pleiotropic eﬀects of these kinds of medications [33–35].Mediators of Inﬂammation 5
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Figure 2:BoxandwhiskerplotsofplasmaconcentrationsofC-reactiveprotein(CRP),interleukin6(IL-6),interleukin1beta(IL-1β),tumor
necrosis factor alpha (TNFα), vascular adhesion molecule 1 (sVCAM-1) and P-Selectin in dyslipidemic subjects with (+CAD; n = 33) or
without (−CAD; n = 69) symptomatic (CAD). ∗P<. 05 versus −CAD. Dotted lines represent the median of the values obtained from
healthy subjects in the same laboratory.
Due to its transversal design, our results do not allow us
to clarify whether the enhanced inﬂammatory process was a
cause or consequence of the cardiovascular event. However,
the diﬀerences in carotid IMT between groups suggest a
role of inﬂammation in the progression of atherosclerosis
and CAD. Moreover, the results strongly suggest that further
elevation of certain inﬂammatory markers, such as CRP,
IL-6, and sVCAM-1, could be considered as markers of
severity of cardiovascular disease and consequently higher
risk of developing a cardiovascular event in dyslipidemic
subjects. Another interesting ﬁnding is the lower TG levels
observed in +CAD patients compared to –CAD. Since there
were no diﬀerences in any pharmacological intervention
that could explain this ﬁnding, we believe that it could be
attributable to the fact that +CAD subjects usually follow
dietary recommendations more strictly that –CAD patients.
Given that age is a factor that can aﬀect the presence
of inﬂammatory markers and endothelial function, one
limitation of this study is the absence of a control group of
age-matched patients with “normal” cholesterol levels with
and without atherosclerosis. Therefore, the obtained results
can only be extrapolated to dyslipidemic subjects.6 Mediators of Inﬂammation
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Figure 3: Scatter plots showing the correlation of intima-media thickness (IMT), and plasma levels of C-reactive protein (CRP; (a), (b)),
interleukin 6 (IL-6; (c), (d)) and vascular adhesion molecule 1 (sVCAM-1; (e), (f)) in dyslipidemic subjects with (+CAD, n = 33) or without
(−CAD,n = 69)symptomaticcoronaryarterydisease.Solidlinesrepresentthebest-ﬁtvaluesforthelinearregression,dashedlinesrepresent
the 95% conﬁdence interval for linear regression, and P-values represent the probability for the slope of each regression being diﬀerent to 0.Mediators of Inﬂammation 7
In summary, the present study indicates that in dys-
lipidemic subjects further elevation of certain inﬂammatory
markers is associated with increased carotid IMT and history
of CAD, but not with further endothelial dysfunction. The
results also suggest that inﬂammatory markers and carotid
IMT, associated with the presence of clinically diagnosed
CAD are partially independent of the lipid proﬁle and the
degree of endothelial dysfunction.
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